MarketCap
Facebook
X
TelegramUrovant Sciences Ltd. Total Non Current Liabilities 2011-2026 | UROV
Annual Total Non Current Liabilities Urovant Sciences Ltd.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 90.4 M | 13.5 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 90.4 M | 13.5 M | 52 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
326 M | $ 3.55 | -0.28 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | Canada |
 |
Adagene
ADAG
|
158 M | $ 3.91 | -2.01 % | $ 220 M |  China |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
9.24 M | $ 3.32 | 6.07 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M | China |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
378 M | $ 4.11 | -2.61 % | $ 105 M | Schweiz |
 |
Aptorum Group Limited
APM
|
2.21 M | $ 0.79 | 0.04 % | $ 4.31 M | China |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arcturus Therapeutics Holdings
ARCT
|
30.4 M | $ 6.39 | -3.62 % | $ 175 M |  Israel |
 |
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | USA |
 |
argenx SE
ARGX
|
226 M | $ 706.03 | 0.39 % | $ 25 B |  Niderland |
 |
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.34 | -7.48 % | $ 8.04 B |  Australia |
 |
Ascendis Pharma A/S
ASND
|
101 M | $ 228.06 | -1.28 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
BioCardia
BCDA
|
1.3 M | $ 1.28 | 0.79 % | $ 27.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
69.2 M | $ 6.13 | 1.32 % | $ 500 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
5.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.63 M | $ 3.43 | -4.19 % | $ 7.46 B | Israel |
 |
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | USA |
 |
Catalyst Biosciences
CBIO
|
981 K | $ 11.1 | -4.15 % | $ 992 M | USA |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
26.1 M | $ 14.51 | 1.04 % | $ 213 M | USA |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
Aptose Biosciences
APTO
|
10.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
14.7 M | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
42.1 M | $ 2.59 | -1.89 % | $ 16.3 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.51 | - | $ 385 M | Britain |
 |
BioNTech SE
BNTX
|
341 M | $ 94.86 | 4.77 % | $ 27.2 B | Germany |
 |
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |